Shots:

• Evotec to receive a up front as well as research funding for biomarker development and CMC and is eligible to receive $361.21M as clinical & commercial milestones along with royalties on the net sales of EVT801- which will be shared with Sanofi (partner in the discovery and the development of EVT801)
• Kazia to get an exclusive WW license for research- development- and commercialization of EVT801. Kazia plans to evaluate EVT801 both as monothx. and in combination with immunotherapy for oncology indications
• Evotec will provide CMC and manage the P-I trial of the therapy while Kazia will responsible for subsequent clinical evaluation & commercialization of EVT801

  Ref: Evotec | Image: Twitter